AbbVie's arthritis medication has been approved by the FDA for a better use
The Food and Drug Administration of the United States has approved the use of AbbVie Inc's arthritis medication to treat eczema and a skin disease, according to the company on Friday.
Patients aged 12 to older have been given the option of Rinvoq for treatment of moderate to severe atopic dermatitis, or eczema.
Substantial delays have occurred in the introduction of the JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases and target a range of autoimmune diseases.
Following the Xeljanz trial, the FDA added the most stringent warning to labels of JAK inhibitor drugs from Pfizer, Eli Lilly, and AbbVie.